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Asthma affects millions of  people worldwide. It is often 
considered to be benign and is therefore under-diagnosed 
and under-treated. In fact asthma can be a very serious 
condition with significant morbidity and mortality. Most of  
the deaths are in patients over the age of  45 and many deaths 
could have been prevented with prompt medical treatment 
and good long term care1. The exact incidence of  asthma 
in Malawi is unknown but it is a common clinical diagnosis. 
Recognising and treating asthma appropriately will save 
lives.
Definition
Diagnosis of  asthma is clinical.  It requires a history of  
variable airways obstruction, with more than one of  the 
following symptoms: wheeze, cough, chest tightness and 
breathlessness2. The symptoms are usually episodic, so 
between ‘asthma attacks’ a patient may be completely well 
and have normal respiratory function. 
Pathogenesis
Asthma is a disease that affects the small and medium 
airways in the lungs (bronchi). It is caused by airway 
hyper-responsiveness and immune activation leading to 
bronchoconstriction, inflammation and increased mucus 
production. These processes narrow the airways and 
cause symptoms of  cough, chest tightness, wheeze and 
breathlessness. 
The exact cause of  asthma is unknown. It is thought to be 
due to a combination of  genetic predisposition and allergen 
exposure. In some patients there is a clear family history of  
asthma, suggesting a stronger genetic component. We also 
know that patients with low birth weights and those born to 
smokers are more likely to develop asthma3.
In an asthmatic patient the airways are more sensitive to 
certain triggers. Once exposed to these triggers, a cascade 
of  inflammation starts - excess autonomic activation leads 
to smooth muscle constriction; immune system activation 
mediated by immunogloubulin E (IgE) increases mast cell 
degranulation and release of  inflammatory cytokines. This 
is associated with increased activation of  eosinophils. Mucus 
production and inflammation of  the bronchial wall lead to 
further airway narrowing. 
Diagnosis - Is it really asthma?
Making a firm diagnosis of  asthma is not as easy as many 
people think. There is no single diagnostic test, and your 
patient may appear in perfect health between attacks. The 
diagnosis is made clinically – the more positive elements there 
are the more likely the diagnosis. A careful history may elicit 
previous episodes of  breathlessness and triggers associated 
with the onset of  symptoms. Recurrent cough is common 
and a nocturnal cough may be the only reported symptom.
Many patients have been diagnosed with asthma as a child. It 
is important to review the history and treatment response in 
these patients to ensure the correct diagnosis. 
A history of  eczema or hay fever (atopy) increases the risk 
of  asthma as does a family history of  asthma or atopy 
(particularly maternal)4. 
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Examination findings can be unhelpful when a patient is 
well, but wheeze will help to confirm your diagnosis. 
Pointers towards a diagnosis of asthma
1. Clinical suspicion of  asthma 
History of  episodes of  wheeze, recurrent breathlessness, 
cough and or chest tightness
Triggers for episodes of  breathlessness
Well between episodes
2. History suggestive of  asthma
Personal history of  recurrent symptoms
History of  childhood asthma
Improvement on treatment
Symptoms worse at night or early morning
Family history of  asthma or atopy (asthma, eczema, allergic 
rhinitis)
3. Examination findings 
Normal
Wheeze and reduced air entry during an attack
4. Trial of  treatment
Clinical improvement on bronchodilators 
5. Investigations
CXR, blood tests
Patients who have a history and examination suggestive of  
asthma, a trial of  treatment is appropriate. They must be 
reviewed for clinical improvement to confirm the suspicion 
of  asthma. If  they do improve, then you can continue the 
asthma therapy with reasonable confidence. If  patients do not 
respond to treatment, other diagnoses must be considered. 
Peak expiratory flow rates (PEFR) should be used to monitor 
the patient both before a trial of  therapy and during it. 
Peak Expiratory Flow Rate (PEFR)
A PEFR or ‘peak flow’ is a measurement of  the fastest air 
flow during forced expiration. When the airways are narrowed 
by bronchoconstriction during an asthma attack, the airflow 
is reduced, so the PEFR falls. The PEFR may start to fall 
before the patient is aware of  symptoms, so can be useful as 
an early warning of  an asthma attack. Patients with asthma 
show more ‘variability’ in their PEFR measurements than 
non-asthmatic patients. This is due to small, often subclinical, 
variations in airway narrowing and bronchoconstriction. 
These variations also help in the diagnosis of  asthma as 
this is a characteristic pattern. The PEFR is measured using 
a PEFR meter (Figure 1). This is simple to use but good 
patient technique is essential for reliable readings. The PEFR 
for each patient will depend on their height, age and sex, so 
each patient with asthma should know what their ‘predicted’ 
(calculated by age, height and sex) or ‘best’ (the PEFR they 
can achieve when well and asymptomatic) PEFR should be. 
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Figure 1.  Peak Expiratory Flow Rate (PEFR) meter
Other investigations
Further investigations are only necessary if  there is still 
diagnostic uncertainty. A chest X-ray may show the typical 
hyper-inflation with flattening of  the diaphragms and 
elongation of  the mediastinal shadow associated with 
asthma. Significant interstitial shadowing, lymphadenopathy 
or scarring and loss of  volume all suggest alternative 
diagnoses. 
Blood tests can be helpful but these tests are not widely 
available in Malawi, and are not necessary in the clinical 
diagnosis of  asthma. 
Spirometry
It is possible to measure flow through the airways using a 
simple piece of  equipment called a spirometer. We measure 
the amount the patient is able to breathe out in one second 
(Forced Expiratory Volume in 1 second, or FEV1). We can 
also measure the total amount a patient is able to breathe out 
(Forced Expiratory Volume, FVC). The actual values vary 
with age, height and sex. The ratio of  the FEV1 to FVC gives 
us a measure of  airway obstruction which reflects airway 
narrowing. As airway narrowing (bronchoconstriction) is 
variable in asthma, the FEV1/FVC ratio will also vary. When 
a patient with asthma is well and has no symptoms, the 
FEV1/FVC ratio will be normal. During an asthma attack, 
or when the patient is less well controlled, the ratio may fall, 
showing obstruction caused by bronchocontriction.
This gives us another helpful test in asthma – if  a reduced 
FEV1/FVC ratio is found (obstructive pattern) then you 
can try to reverse the obstruction by giving the patient a 
bronchodilator such as inhaled salbutamol. This reduces the 
bronchoconstriction, improving air flow out of  the lungs, 
and the FEV1/FVC ratio will normalise. The obstruction 
is gone. This demonstrates ‘reversibility’ which is a key 
feature of  asthma and explains how the patient’s symptoms 
come and go. Other diseases that cause airway narrowing 
and an obstructive pattern on spirometry (such as Chronic 
Obstructive Lung Disease, COPD), are not readily reversible, 
so even with salbutamol the FEV1/FVC ration will remain 
the reduced. 
Triggers
Many patients with asthma are able to identify ‘triggers’ that 
precipitate an attack. This may be tree or grass pollen, dust, 
road pollution, exercise or even a change in the weather. 
Identifying these triggers helps people to predict when they 
will feel symptomatic, and therefore to either avoid the trigger 
completely (cigarette smoke) or to increase their medication 
accordingly (weather). 
However we also know that certain oral medications worsen 
asthma. Some of  these, such as B adrenergic receptor 
antagonists (B blockers) cause bronchial smooth muscle 
constriction so narrowing the airway and worsening symptoms 
of  asthma. Others, such as aspirin and non-steroidal anti-
inflammatory drugs (NSAIDS) act by blocking the COX1 
enzyme and worsen asthmatic symptoms5. However not all 
patients with asthma will have hypersensitivity to NSAIDS 
and aspirin6. 
Management of asthma in Malawi 
Bronchodilation
Bronchodiation is essential to control of  acute episodes 
of  asthma and salbutamol is the most commonly available 
bronchodilator in Malawi. It is a short acting beta-agonist, 
which works on beta adrenergic receptors in the lung causing 
smooth muscle relaxation and bronchodilation. Salbutamol 
also acts on the cardiac muscle where it has a stimulatory 
effect, causing tachycardia. 
Salbutamol can be given as an inhaled preparation, as a 
nebuliser, orally or, in extreme circumstances, intravenously. 
The method of  delivery determines the rate of  onset of  
action and likely side effects. Oral salbutamol has a slower rate 
of  onset – it has to be absorbed by the gut, but has a more 
prolonged action when compared to inhaled salbutamol7.
However the side effects from oral salbutamol are often 
more pronounced (palpitations and tremor) and the slow 
onset of  action limits its use in acute settings8. 
Inhaled salbutamol has a direct effect on the smooth muscle 
of  the bronchi, with only a small proportion absorbed into 
the systemic circulation. It is possible to give high doses 
of  inhaled salbutamol before the side effects become 
problematic. However this only works if  the inhaler is used 
properly. Many patients find using an inhaler very difficult 
even after repeated practice. 
To sidestep the issue of  inhaler technique, patients using a 
salbutamol inhaler should be taught to use a spacer device. 
This allows the patient to inhale the salbutamol with little 
need for co-ordination. They simply dispense the inhaler into 
one end of  the ‘spacer’ and breathe normally from the other. 
It is possible to buy a spacer device, but it is also possible to 
make one yourself  from a plastic water bottle (Figure 2) 
Figure 2.  ‘Spacer’ made from a water or Sobo bottle
 Figure 3.  The spacer being used
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In the emergency setting, nebulised salbutamol is the most 
effective method of  drug delivery. It does not require any 
co-ordination from the patient, and has a very rapid onset. 
The nebulisers should be repeated every 15 minutes until 
the patient improves. If  a nebuliser is not available, inhaled 
salbutamol via a spacer is a good alternative. 
Alternative bronchodilators include anticholinergic drugs, 
such as inhaled or nebulised ipratropium bromide. This is 
rarely available in Malawi. Adrenaline can also be used as a 
nebuliser if  salbutamol is not available.  
Steroids
All patients seen with an acute exacerbation of  asthma need a 
short course of  steroids. Steroids have a slow onset of  action 
(4-6 hours, regardless of  route of  administration) but have 
an essential role in reducing the inflammation in the airways. 
Five days is normally appropriate. If  your patient has been 
taking steroids for more than 10-14 days you should consider 
a tapering dose. Equally, all patients with regular symptoms 
of  asthma – those who attend hospital for nebulisers, or use 
their inhalers more than 2-3 times a week, should be on a 
steroid inhaler. Steroid inhalers can (and should) be given via 
a spacer device.  
Other medications for asthma
Magnesium sulphate is another drug used in acute asthma. 
The mechanism is unclear, but it is thought to stabilise 
mast cells and therefore reduce the ongoing inflammatory 
response. 
Aminophylline is commonly used both in oral and 
intravenous forms. It is a methyxanthine (like caffeine) and 
has two main effects - it acts as an anti-inflammatory and also 
stimulates the central nervous system. Used regularly in oral 
form it can help to control asthma symptoms. It is used in 
the emergency setting for people with severe exacerbations. 
Patients who take oral aminophylline do not need to be given 
an intravenous loading dose. 
Complications of asthma – common pitfalls
When a patient is deteriorating or fails to improve on 
treatment, there are several things that need to be considered. 
Most commonly the patient has simply not received enough 
bronchodilation therapy. However there are some other 
common complications that need to be considered. 
Exhaustion is a serious consequence of  a prolonged asthma 
attack - recognised by poor respiratory effort, reduced 
alertness and a falling respiratory rate. These patients 
need urgent anaesthetic review. Another cause of  acute 
deterioration in an asthmatic is pneumothorax. This is a 
reversible life threatening event, and can be easily missed if  
you are not alert to the risk. Mucus plugging of  the bronchi 
can cause acute deterioration – keeping your patient well 
hydrated, and encouraging her to cough will help. Chest 
physiotherapy is of  great benefit if  available. Infection is 
another common cause of  either prolonged exacerbation 
or deterioration. Not all patients with acute asthma need 
antibiotics, but this should be considered in those with fever 
or purulent sputum. 
Other problems
Patients who have not responded to treatment should 
be reassessed for alternative diagnoses. Diseases that can 
mimic asthma include chronic obstructive pulmonary 
disease, congestive cardiac failure (with a ‘cardiac wheeze’) 
and sarcoidosis (chronic cough and shortness of  breath). 
Unilateral or localised wheeze should always raise the 
possibility of  a focal obstructive lesion such as a foreign 
body or tumour. Acute allergy and anaphylaxis also cause 
acute bronchoconstriction, but do not warrant long-term 
bronchodilators. A thorough history and examination will 
help to differentiate between these conditions. 
Special cases of asthma
Chronic asthma
Patients whose asthma has been well controlled over the 
years may remain totally asymptomatic between attacks. 
However if  a patient’s asthma has been undertreated (often 
either because of  late diagnosis or poor adherence) they may 
develop chronic symptoms of  gradually progressive shortness 
of  breath, recurrent exacerbations and examination findings 
of  hyperexpansion with reduced chest wall movement. 
This is due to chronic inflammation in the airways, with 
subsequent airways remodelling and irreversible narrowing. 
These patients may still have ‘asthma attacks’ but may remain 
short of  breath or wheezy between episodes.  
Asthma in Pregnancy
Asthma often worsens in pregnancy. Patients suffer from 
more frequent and more severe attacks. Pregnant women 
with asthma should continue on all their normal medication 
and should have their treatment escalated as needed9. 
Asthma is a common and highly variable chronic disease. It 
can be fatal, but usually responds well to prompt treatment. 
Careful out patient management is needed to prevent long 
term breathlessness and reduce emergency admissions. 
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